Ethel D Weld, Ian McGowan, Peter Anton, Edward J Fuchs, Ken Ho, Alex Carballo-Dieguez, Lisa C Rohan, Rebecca Giguere, Rhonda Brand, Stacey Edick, Rahul P Bakshi, Teresa Parsons, Madhuri Manohar, Aaron Seigel, Jared Engstrom, Julie Elliott, Cindy Jacobson, Christina Bagia, Lin Wang, Amer Al-Khouja, Douglas J Hartman, Namandje N Bumpus, Hans M L Spiegel, Mark A Marzinke, Craig W Hendrix
BACKGROUND: Despite highly effective HIV preexposure prophylaxis (PrEP) options, no options provide on-demand, nonsystemic, behaviorally congruent PrEP that many desire. A tenofovir-medicated rectal douche before receptive anal intercourse may provide this option. METHODS: Three tenofovir rectal douches-220 mg iso-osmolar product A, 660 mg iso-osmolar product B, and 660 mg hypo-osmolar product C-were studied in 21 HIV-negative men who have sex with men. We sampled blood and colorectal tissue to assess safety, acceptability, pharmacokinetics, and pharmacodynamics...
April 12, 2024: Journal of Infectious Diseases